Trial Profile
A randomized, open label study to determine the immunological benefits of adding Fuzeon [enfuvirtide] to an antiretroviral regimen in HIV-infected Fuzeon-naive patients with sustained HIV viral suppression
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Enfuvirtide (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms ESP
- Sponsors Roche
- 23 Aug 2016 Status changed from discontinued to withdrawn prior to enrolment.
- 25 Mar 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 29 Jun 2007 New trial record.